NeoGenomics (NEO) said Friday that it has acquired Pathline, a New Jersey-based laboratory, to strengthen its commercial presence in the Northeast US, expand service capabilities, and accelerate growth in molecular and hematology-oncology testing.
The company said it expects the deal to be accretive to adjusted Ebitda starting next year.
Financial details of the deal were not disclosed.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.